

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10599892
	Filing Date		2006-10-12
	First Named Inventor		Aloke K. Dutta
	Art Unit		1626
	Examiner Name		Unknown
	Attorney Docket Number		WSU 0203 PUSA

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS						Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>5</sup>
						<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.C./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10599892
	Filing Date	2006-10-12
	First Named Inventor	Aloke K. Dutta
	Art Unit	1626
	Examiner Name	Unknown
	Attorney Docket Number	WSU 0203 PUSA

1	[Pub44.pdf]: Dutta, A.K., Davis, M.C., Reith, M. E. A. Rational Design and synthesis of novel conformationally constrained 2,5-disubstituted cis- and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter. <i>Bioorg. Med. Lett.</i> 2001, 11, 2337-2340.	<input type="checkbox"/>
2	[Pub45.pdf]: Kolhatkar R.B., Ghorai S.K., George C, Reith M. E. A, Dutta A K. Interaction of cis-(6- benzhydryl-piperidin-3-yl)-benzyl-amine analogs with monoamine transporters: Structure Activity Relationship study of structurally constrained 3,6-disubstituted piperidine analogs of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidine-4-ylmethyl]amine. <i>J. Med. Chem.</i> 2003, 46, 2205-2215.	<input type="checkbox"/>
3	[Pub46.pdf]: Zhang S, Reith M E A, Dutta A K. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. <i>Bioorg. Med. Chem. Lett.</i> 13, 1591-1595, 2003.	<input type="checkbox"/>
4	[Pub47.pdf]: Zhang, S., Zhen, J., Reith, M.E.A., Dutta, A.K., "Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters," <i>Bioorganic Medicinal Chemistry</i> , 2004, 12, 6301-6315.	<input type="checkbox"/>
5	[Pub48.pdf]: J. Langston et al., "MPTP: Current Concepts and Controversies," <i>Clin. Neuropharmac.</i> , 1986, 9, 485-507.	<input type="checkbox"/>
6	[Pub49.pdf]: Cookson, "J. Side Effects of Antidepressants," <i>Br. J. Psychiatry</i> , 20, 20-24, 1993	<input type="checkbox"/>
7	[Pub50.pdf]: A.K. Dutta et al., "Positional Importance of the Nitrogen Atom in Novel Piperidine Analogs of GBR 12909: Affinity and Selectivity for the Dopamine Transporter," <i>Med. Chem. Res.</i> , 1993, 3, 209-222	<input type="checkbox"/>
8	[Pub51.pdf]: Shoemaker, H., et al., "Naunyn Schmiedebergs Arch. Pharmacol., 1985, 329, 227-235	<input type="checkbox"/>
9	[Pub52.pdf]: Baker Botts, "In Prints - Reach-Through Claims," <a href="http://www.bakerbotts.com/news/printpage.asp?pubid=19221417">http://www.bakerbotts.com/news/printpage.asp?pubid=19221417</a> (2 pgs.)	<input type="checkbox"/>
10	[Pub53.pdf]: Gourley, D.R.H., "Biological Responses to Drugs," <i>Medicinal Chemistry</i> , 3rd Ed., Part I, p. 25	<input type="checkbox"/>
11	[Pub54.pdf]: Zhang, S., et al., "Design, Synthesis, and Preliminary SAR Study of 3- and 6-Side Chain Extended Tetrahydro-Pyran Analogues of cis- and trans-(6-benzhydryl-piperidin-3-yl)-benzylamine," <i>Bioorg. Med. Chem.</i> 14, 3953-3966, 2006	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.C./  
EFS Web 2.0

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10599892
	Filing Date	2006-10-12
	First Named Inventor	Aloke K. Dutta
	Art Unit	1626
	Examiner Name	Unknown
	Attorney Docket Number	WSU 0203 PUSA

12	[Pub37.pdf]: Koch, S., Hemrick-Luecke, S., Thompson, L., Evans, D., Threlkeld, P., Nelson, D., Perry, K., Bymaster, F. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. <i>Neuropharmacology</i> . 2003, 45, 935-944.	<input type="checkbox"/>
13	[Pub38.pdf]: Nemeroff, C. B. Psychopharmacology of affective disorders in the 21= century. <i>Biol. Psychiatry</i> . 44, 517-525, 1998.	<input type="checkbox"/>
14	[Pub39.pdf]: Iverson, L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. <i>Mol. Psychiatry</i> . 5, 357-362, 2000.	<input type="checkbox"/>
15	[Pub40.pdf]: Schloss, P., Williams, D. C. The serotonin transporter: a primary target for antidepressant drugs. <i>J. Psychopharmacol.</i> 12, 115-121, 1998.	<input type="checkbox"/>
16	[Pub41.pdf]: Feighner, J. P. Mechanism of action of antidepressant medications. <i>J. Clin. Psychiatry</i> . 60, 4-11, 1999.	<input type="checkbox"/>
17	[Pub42.pdf]: Pinder, R. M., Wieringa, J. H. Third-generation antidepressants. <i>Med. Res. Rev.</i> 13, 259-325, 1993.	<input type="checkbox"/>
18	[Pub43.pdf]: Barbey, J. T., Roose, S. P. SSRI safety in overdose. <i>J. Clin. Psychiatry</i> . 59 Suppl 15:42--8, 1998.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	/Raymond Covington/ au 1625	Date Considered	2/22/2010
--------------------	-----------------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.C./